Fouque, Amelie; Delalande, Olivier; Jean, Mickael; Castellano, Remy; Josselin, Emmanuelle; Malleter, Marine; Shoji, Kenji F.; Hung, Mac Dinh; Rampanarivo, Hariniaina; Collette, Yves; Weghe, Pierre van de; Legembre, Patrick published the artcile< A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells>, Electric Literature of 3893-18-3, the main research area is covalent mTOR inhibitor DHM25 antitumor breast cancer.
Constitutive activation of the PI3K/mTOR signaling pathway contributes to carcinogenesis and metastasis in most, if not all, breast cancers. From a chromene backbone reported to inhibit class I PI3K catalytic subunits, several rounds of chem. syntheses led to the generation of a new collection of chromologues that showed enhanced ability to kill PI3K-addicted cancer cells and to inhibit Akt phosphorylation at serine 473, a hallmark of PI3K/mTOR activation. This initial screen uncovered a chromene designated DHM25 that exerted potent antitumor activity against breast tumor cell lines. Strikingly, DHM25 was shown to be a selective and covalent inhibitor of mTOR using biochem. and cellular analyses, modeling, and a large panel of kinase activity assays spanning the human kinome (243 kinases). Finally, in vivo, this novel drug was an efficient inhibitor of growth and metastasis of triple-neg. breast cancer cells, paving the way for its clin. application in oncol.
Journal of Medicinal Chemistry published new progress about Antitumor agents. 3893-18-3 belongs to class bromides-buliding-blocks, and the molecular formula is C9H7BrO, Electric Literature of 3893-18-3.
Referemce:
Bromide – Wikipedia,
bromide – Wiktionary